<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301078</url>
  </required_header>
  <id_info>
    <org_study_id>Pain and Function - PNA vs CCH</org_study_id>
    <nct_id>NCT02301078</nct_id>
  </id_info>
  <brief_title>Short-term Function and Pain After Treatment for Dupuytren's Disease</brief_title>
  <official_title>Comparing Short-term Function and Pain After Treatment With Collagenase Clostridium Histolyticum or Percutaneous Needle Aponeurotomy for Dupuytren's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate short-term pain and function associated with percutaneous needle
      aponeurotomy (PNA) and injections of the enzyme collagenase clostridium histolyticum in
      patients with Dupuytren's disease. Scores on outcome measures will be compared between groups
      to determine whether treatments differ in terms of hand function and pain during the early
      post-treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous needle aponeurotomy (PNA) and injections of the enzyme collagenase clostridium
      histolyticum are two non-invasive treatment options for patients with Dupuytren's disease.
      While PNA has been offered for decades, injectable collagenase is relatively new. The
      effectiveness of each treatment has been compared in the literature; however, recovery, in
      terms of pain and short-term function has not been formally evaluated. The objective of this
      study is to objectively compare short-term function and pain outcomes associated with each of
      these two procedures in patients presenting with untreated Dupuytren's disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Michigan Hand Questionnaire (brief MHQ)</measure>
    <time_frame>Baseline</time_frame>
    <description>A validated patient-reported 12-item questionnaire pertaining to several aspects of hand function that is answered on 1 through 5 Likert scales. Higher scores indicate better hand function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unite Rhumatologique des Affections de la Main (URAM) scale</measure>
    <time_frame>Baseline</time_frame>
    <description>The URAM is a validated patient-reported 9-item functional assessment scale used clinically and for research purposes specific to patients with Dupuytren's disease. The resulting score quantifies Dupuytren's disease-related disability, with higher scores indicating higher level of disability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Pain and Function Scales</measure>
    <time_frame>Baseline</time_frame>
    <description>An emailed form asking participants to rate pain and function during the past 24 hours using two 1-5 Likert scales. Two additional questions to assess night splint compliance and pain medication (yes/no)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Michigan Hand Questionnaire (brief MHQ)</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Michigan Hand Questionnaire (brief MHQ)</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Michigan Hand Questionnaire (brief MHQ)</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Michigan Hand Questionnaire (brief MHQ)</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unite Rhumatologique des Affections de la Main (URAM) scale</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unite Rhumatologique des Affections de la Main (URAM) scale</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unite Rhumatologique des Affections de la Main (URAM) scale</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unite Rhumatologique des Affections de la Main (URAM) scale</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Pain and Function Scales</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Pain and Function Scales</measure>
    <time_frame>Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Pain and Function Scales</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Pain and Function Scales</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Pain and Function Scales</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Pain and Function Scales</measure>
    <time_frame>Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Pain and Function Scales</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Pain and Function Scales</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Pain and Function Scales</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Pain and Function Scales</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dupuytren Disease</condition>
  <arm_group>
    <arm_group_label>Percutaneous Needle Aponeurotomy</arm_group_label>
    <description>Patients who choose to undergo percutaneous needle aponeurotomy (PNA) for primary treatment of Dupuytren's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xiaflex</arm_group_label>
    <description>Patients who choose to receive Collagenase clostridium histolyticum injection (drug name Xiaflex) for primary treatment of Dupuytren's disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Needle Aponeurotomy</intervention_name>
    <description>single procedure (day 0)</description>
    <arm_group_label>Percutaneous Needle Aponeurotomy</arm_group_label>
    <other_name>needle aponeurotomy</other_name>
    <other_name>fasciotomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Collagenase clostridium histolyticum</intervention_name>
    <description>Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)</description>
    <arm_group_label>Xiaflex</arm_group_label>
    <other_name>Xiaflex</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at Sunnybrook Health Sciences Centre choosing either percutaneous needle
        aponeurotomy or Xiaflex injection for treatment of Dupuytren's disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult

          -  Dupuytren's disease diagnosis

          -  Consented to either percutaneous needle aponeurotomy or Xiaflex injection (patient
             choice)

          -  Able to read/write/speak English

          -  Must have an email address

        Exclusion Criteria:

          -  Previous treatment for Dupuytren's disease

          -  Type 2 Diabetes Mellitus

          -  Pre-existing hand condition, previous hand surgery or trauma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre, Division of Plastic and Reconstructive Surgery</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine McMillan, MSc</last_name>
      <email>catherine.mcmillan@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Paul A. Binhammer, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dupuytren disease</keyword>
  <keyword>needle aponeurotomy</keyword>
  <keyword>collagenase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dupuytren Contracture</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

